Premium
Transporters in Drug‐Refractory Epilepsy: Clinical Significance
Author(s) -
Marchi N,
GonzalezMartinez J,
Nguyen MT,
Granata T,
Janigro D
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2009.225
Subject(s) - clinical pharmacology , epilepsy , medicine , drug , drug resistance , refractory (planetary science) , pharmacology , intensive care medicine , bioinformatics , psychiatry , biology , genetics , astrobiology
Drug resistance remains an unmet challenge in a variety of neurological disorders, but epilepsy is probably the refractory disease that has received most experimental, preclinical, and therapeutic attention. Although resective surgery continues to improve our ability to provide seizure relief, new discoveries have potential as alternative therapeutic approaches to multiple drug resistance. As discussed here, the field is replete with controversies and false starts, in particular as it concerns the existence of genetic predisposition to inadequate pharmacological seizure control. Clinical Pharmacology & Therapeutics (2010) 87 1, 13–15. doi: 10.1038/clpt.2009.225